IRIS  Catalogo Istituzionale della Ricerca dell'Università degli Studi del Molise

LUBRANO DI SCORPANIELLO, Ennio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.654
EU - Europa 10.988
AS - Asia 4.293
SA - Sud America 1.207
AF - Africa 547
OC - Oceania 28
Continente sconosciuto - Info sul continente non disponibili 17
Totale 31.734
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.379
RU - Federazione Russa 4.924
IE - Irlanda 1.964
SG - Singapore 1.953
BR - Brasile 924
CN - Cina 867
IT - Italia 675
FR - Francia 582
UA - Ucraina 548
DE - Germania 475
FI - Finlandia 460
AT - Austria 374
CI - Costa d'Avorio 357
VN - Vietnam 337
SE - Svezia 333
GB - Regno Unito 325
HK - Hong Kong 206
IN - India 189
BD - Bangladesh 169
CA - Canada 136
AR - Argentina 93
MX - Messico 77
IQ - Iraq 70
JP - Giappone 68
TR - Turchia 68
ZA - Sudafrica 65
NL - Olanda 61
PL - Polonia 59
EC - Ecuador 45
ES - Italia 44
CO - Colombia 43
ID - Indonesia 42
PK - Pakistan 41
BE - Belgio 40
VE - Venezuela 37
SA - Arabia Saudita 32
LT - Lituania 27
MA - Marocco 26
AU - Australia 22
PH - Filippine 22
AZ - Azerbaigian 20
CL - Cile 20
UZ - Uzbekistan 20
IR - Iran 19
IL - Israele 18
MY - Malesia 18
TN - Tunisia 18
EG - Egitto 17
KR - Corea 16
KZ - Kazakistan 16
JO - Giordania 15
BO - Bolivia 14
EU - Europa 14
DZ - Algeria 13
JM - Giamaica 13
KE - Kenya 12
RO - Romania 12
AE - Emirati Arabi Uniti 11
NP - Nepal 11
PE - Perù 11
CZ - Repubblica Ceca 10
HR - Croazia 10
PY - Paraguay 10
UY - Uruguay 10
PA - Panama 9
PT - Portogallo 9
CH - Svizzera 8
KG - Kirghizistan 8
OM - Oman 8
TH - Thailandia 8
TT - Trinidad e Tobago 8
AL - Albania 7
ET - Etiopia 7
SN - Senegal 7
BG - Bulgaria 6
DO - Repubblica Dominicana 6
GE - Georgia 6
GR - Grecia 6
CR - Costa Rica 5
LB - Libano 5
LK - Sri Lanka 5
LV - Lettonia 5
NI - Nicaragua 5
NZ - Nuova Zelanda 5
PS - Palestinian Territory 5
AO - Angola 4
DK - Danimarca 4
GT - Guatemala 4
KW - Kuwait 4
SK - Slovacchia (Repubblica Slovacca) 4
BY - Bielorussia 3
CY - Cipro 3
HU - Ungheria 3
NO - Norvegia 3
SV - El Salvador 3
XK - ???statistics.table.value.countryCode.XK??? 3
GI - Gibilterra 2
HN - Honduras 2
KN - Saint Kitts e Nevis 2
LA - Repubblica Popolare Democratica del Laos 2
Totale 31.691
Salva come PNG Salva come JPEG
Città #
Dallas 4.381
Dublin 1.963
Moscow 1.655
San Jose 1.486
Jacksonville 1.323
Chandler 1.133
Singapore 1.030
Ashburn 587
The Dalles 434
Wilmington 409
Vienna 366
Abidjan 357
Helsinki 316
Rome 287
Houston 265
Beijing 249
San Mateo 248
Lauterbourg 227
Hong Kong 203
Ann Arbor 185
Princeton 179
Los Angeles 177
Boardman 148
Woodbridge 146
New York 132
Ho Chi Minh City 122
Frankfurt am Main 112
Columbus 106
Santa Clara 106
Council Bluffs 99
Dearborn 94
São Paulo 87
Tokyo 63
Orem 62
Hanoi 60
Warsaw 48
Toronto 44
Amsterdam 43
Brooklyn 42
Chicago 42
Redwood City 41
London 39
Chennai 38
Rio de Janeiro 38
Johannesburg 37
San Francisco 37
Montreal 36
Mountain View 36
Brussels 35
Denver 35
Molise 34
Milan 33
Mexico City 32
Atlanta 30
Hillsboro 28
Manchester 28
Jinan 27
Dhaka 26
Nuremberg 25
Baghdad 24
Seattle 21
Boston 20
Shanghai 20
Baku 19
Nanjing 19
Shenyang 18
Tashkent 18
Falls Church 17
Guangzhou 17
Istanbul 17
Lahore 17
Phoenix 17
Caracas 16
Ottawa 16
Naples 15
Amman 14
Augusta 14
Mumbai 14
Ningbo 14
Stockholm 14
Auburn Hills 13
Jakarta 13
Leawood 13
Porto Alegre 13
Quito 13
Belo Horizonte 12
Buffalo 12
Fortaleza 12
Haikou 12
Paris 12
Poplar 12
Bogotá 11
Brasília 11
Campinas 11
Curitiba 11
Falkenstein 11
Guayaquil 11
Haiphong 11
La Paz 11
Nairobi 11
Totale 20.248
Salva come PNG Salva come JPEG
Nome #
A 12-point recommendation framework to support advancement of the multidisciplinary care of psoriatic arthritis: A call to action 2.732
An ultrasonographic study of enthesis in early psoriatic arthritis patients naive to traditional and biologic DMARDs treatment 248
Assessment of response to treatment, remission, and minimal disease activity in axial psoriatic arthritis treated with tumor necrosis factor inhibitors 219
An Assessment of Hand Erosive Osteoarthritis: Correlation of Radiographic Severity with Clinical, Functional and Laboratory Findings 216
Analysis of potential determinants for a treat-to-target strategy in psoriatic arthritis patients from a real-world setting 210
An overview of low disease activity and remission in psoriatic arthritis. 207
An audit of anthropometric measurements by medical and physiotherapy staff in patients with ankylosing spondylitis 205
ANTHROPOMETRIC MEASUREMENTS AND DISABILITY IN A OPEN FOLLOW UP STUDY ON ANKYLOSING SPONDYLITIS WITH COMBINED MEDICAL AND REHABILITATIVE TREATMENT 196
Assessment of bone morphogenic protein 2 and interleukine-17A in patients with axial spondyloarthritis and their potential role in the new bone formation: a cross-sectional study 190
Chronic periaortitis with retroperitoneal fibrosis successfully treated with first line tocilizumab monotherapy: a case report 186
Aortic involvement in ankylosing spondylitis 184
Assessment of subclinical atherosclerosis in ankylosing spondylitis: Correlations with disease activity indices 184
A novel biological target for the treatment of psoriatic arthritis. 183
Antiphospholipid syndrome, activated protein C resistance and mutation C -> T 677 in the MTHFR gene with juvenile pulmonary embolism. A case report 183
Beyond TNF Inhibitors: New Pathways and Emerging Treatments for Psoriatic Arthritis 183
Assessment of semaphorin 3A and its role in bone remodelling in a group of ankylosing spondylitis patients 182
Beyond the joint: Subclinical atherosclerosis in rheumatoid arthritis 181
From clinical remission to residual disease activity in spondyloarthritis and its potential treatment implications 177
Assessment of the Patient Acceptable Symptom State (PASS) in psoriatic arthritis: Association with disease activity and quality of life indices 176
A rare enthesopathy in psoriatic oligoarthritis 174
A national survey on the management of psoriatic arthritis using the Delphi method 170
Cardiovascular Risk Prediction in Ankylosing Spondylitis: From Traditional Scores to Machine Learning Assessment 169
Remission in ankylosing spondylitis treated with anti-TNF-α drugs: a national multicentre study. 168
La spondilodiscite delle spondiloartriti sieronegative 168
Measuring psoriatic disease in clinical practice. An expert opinion position paper. 165
Assessment of psoriatic nail disease activity by rheumatologists 165
Validity and reliability of an Italian version of the revised Leeds disability questionnaire for patients with ankylosing spondylitis 164
Incidence of rheumatoid arthritis, psoriatic arthritis and polymyalgia rheumatica in an inland area of central Italy: results of the CAMPO-RHE study 162
The arthritis of coeliac disease: prevalence and pattern in 200 adult patients 159
Iperuricemia e rischio cardio-renale 159
Venous thrombophilia in a patient with protein S deficiency, factor V Leiden and homozygous MTHFR C -> T677 mutation 156
Validity, responsiveness and feasibility of an Italian version of the Canadian Occupational Performance Measure for patients with ankylosing spondylitis 156
Pharmacoeconomic issues in psoriatic arthritis 154
Joint symmetry in early and late rheumatoid and psoriatic arthritis: comparison with a mathematical model 154
Supervised training and home-based rehabilitation in patients with stabilized ankylosing spondylitis on TNF inhibitor treatment: a controlled clinical trial with a 12-month follow-up 154
Unmet needs in outcome measures of Psoriatic Arthritis: focus on axial radiographic and nail involvement 154
Simple clinical indicators for early psoriatic arthritis detection. 154
Sustained Very Low Disease Activity and Remission in Psoriatic Arthritis Patients 154
The arthritis of ulcerative colitis: clinical and genetic aspects 153
Multidisciplinary Management of Spondyloarthritis-Related Immune-Mediated Inflammatory Disease 153
Assessment of widespread and extra-articular pain in psoriatic arthritis: a case-control study 151
Can traditional disease-modifying anti-rheumatic drugs be withdrawn or tapered in psoriatic arthritis? 150
Somatic perception in irritable bowel syndrome (IBS) patients with and without fibromyalgia (FMS). Does the severity of IBS influence the perception of somatic stimuli? 150
Impact of Comorbidities on Disease Activity, Patient Global Assessment, and Function in Psoriatic Arthritis: A Cross-Sectional Study 150
Patient's global assessment as an outcome measure for psoriatic arthritis in clinical practice: A surrogate for measuring low disease activity? 149
Switching from infliximab or etanercept to adalimumab in resistant or intolerant patients with spondyloarthritis: a 4-year study 148
Assessment of Patient-Physician Interactions in Psoriatic Arthritis: National Results of the ASSIST Study 146
Patient education in psoriatic arthritis: a cross sectional study on knowledge by a validated self-administered questionnaire 146
Is the Nail Psoriasis Severity Index reliable in the assessment of nail psoriasis by rheumatologists? 145
Subcutaneous anti-TNF alfa induced sustained minimal disease activity and remission in psoriatic arthritis patients: a retrospective study 145
Mesenchimal stem cells: A possible role in the pathogenesis and treatment of spondyloarthritis 144
The performance of CASPAR criteria in early psoriatic arthritis - preliminary results from an Italian prospective multicentric study 143
An International Multidisciplinary Delphi-Based Consensus on Heat Therapy in Musculoskeletal Pain 141
Treatment of psoriatic arthritis and rheumatoid arthritis with disease modifying drugs -- comparison of drugs and adverse reactions 141
The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy 141
The role of IL-17 in the treatment of psoriatic arthritis 140
Remission in nonradiographic axial spondyloarthritis treated with anti-tumor necrosis factor-α drugs: an Italian multicenter study. 139
Venous thrombophilia with severe mesenteric involvement associated to homozygosity for factor V Leiden and heterozygosity for G20210A mutation of prothrombin 138
Residual disease activity in rheumatoid arthritis patients treated with subcutaneous biologic drugs that achieved remission or low disease activity: a longitudinal observational study 138
Consensus on the management of patients with psoriatic arthritis in a dermatology setting 138
Validation of the Italian version of proposed GRAPPA flare questionnaire for patients with psoriatic arthritis 138
Cardiovascular comorbidities in psoriatic arthritis: epidemiology and risk factors in two different European populations 137
Psoriatic arthritis: imaging techniques 137
Validity of the modified stoke ankylosing spondylitis spine score (M-SASSS) and of the bath ankylosing spondylitis radiology index (BASRI) for the radiological assessment of axial involvement in psoriatic arthritis. multicentre validation study. Part one. 137
The assessment of knowledge in ankylosing spondylitis patients by a self-administered questionnaire 137
Predictive factors for partial remission according to the Ankylosing Spondylitis Assessment Study working group in patients with ankylosing spondylitis treated with anti-TNFα drugs 136
Axonal degeneration in systemic sclerosis can be reverted by factors improving tissue oxygenation 136
Comparison of composite indices tailored for psoriatic arthritis treated with csDMARD and bDMARD: A cross-sectional analysis of a longitudinal cohort 136
Pharmacoeconomic burden in the treatment of psoriatic arthritis: from systematic reviews to real clinical practice studies 136
Qualifying Unmet Needs and Improving Standards of Care in Psoriatic Arthritis. 135
Fibromyalgia is strongly associated with the severity of inflammatory bowel syndrome. 133
The effectiveness of a biologic agent on axial manifestations of psoriatic arthritis. A twelve months observational study in a group of patients treated with etanercept 133
Constrictive Pericarditis With Massive Calcification in Systemic Sclerosis Treated With Pericardiectomy: A Case Report 132
An international multi-centre analysis of current prescribing practices and shared decision-making in psoriatic arthritis 132
The adherence to ASAS classification criteria and to ASAS recommendations for the use of anti-TNH-alpha agents in axial spondyloarthritis. 132
The radiological assessment of axial involvement in psoriatic arthritis: a validation study of the BASRI total and the modified SASSS scoring methods. 132
Patient global assessment in psoriatic arthritis: a multicenter GRAPPA and OMERACT study 132
Long-term costs and outcomes in psoriatic arthritis patients not responding to conventional therapy treated with tumour necrosis factor inhibitors: An extension of the Psoriatic Arthritis Cost Evaluation (PACE) study 132
Profile of ustekinumab and its potential in the treatment of active psoriatic arthritis 131
Updated guidelines for the management of axial disease in psoriatic arthritis 131
New insights in occult psoriatic arthritis 131
Predictors of loss of remission and disease flares in patients with axial spondyloarthritis receiving antitumor necrosis factor treatment: A retrospective study 130
Unmet Needs in Axial Spondyloarthritis 130
Multimorbidity and comorbidity in psoriatic arthritis–a perspective 130
Current evidence in the field of the management with TNF-α inhibitors in psoriatic arthritis and concomitant hepatitis C virus infection. 129
Physical trauma triggers psoriasis in a patient with undifferentiated seronegative spondyloarthropathy 129
Minimal Disease Activity and Remission in Psoriatic Arthritis Patients Treated with Anti-TNF-α Drugs 129
Management of psoriatic arthritis in rheumatology and dermatology settings: sub-analysis of the Italian population from the international LOOP study 129
Dactylitis and Early Onset Psoriasis in Psoriatic Arthritis: Are they Markers of Disease Severity? A Clinical Study 128
Trauma and seronegative spondylarthropathy 128
Subcorneal pustular dermatosis (Sneddon-Wilkinson syndrome): another cutaneous manifestation of SAPHO syndrome? 128
Recommendations for the use of biologic therapy in the treatment of psoriatic arthritis: update from the Italian Society for Rheumatology 128
Latent tuberculosis infection detection and active tuberculosis prevention in patients receiving anti-TNF therapy: an Italian nationwide survey. 128
Tumour necrosis factor alpha inhibitor therapy and rehabilitation for the treatment of ankylosing spondylitis: A systematic review. 128
Role of comorbidities in spondyloarthritis including psoriatic arthritis 128
Difficult-to-treat concept in Psoriatic Arthritis: analysis of two potential definitions in a large group of patients. A cross-sectional study 127
Clues to the pathogenesis of psoriasis and psoriatic arthritis from imaging: a literature review 126
Treatment options: NSAIDs and DMARDs 126
Defining low disease activity states in psoriatic arthritis using novel composite disease instruments 126
Secukinumab for ankylosing spondylitis and psoriatic arthritis 126
Totale 17.739
Salva come PNG Salva come JPEG
Categoria #
all - tutte 136.995
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 136.995
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202151 0 0 0 0 0 0 0 0 0 0 0 51
2021/2022968 51 252 16 31 55 28 29 106 141 154 43 62
2022/20234.662 535 121 102 392 245 377 16 220 2.328 146 82 98
2023/2024855 238 133 55 21 30 72 18 47 19 47 84 91
2024/20253.476 460 120 432 92 544 143 60 258 306 114 431 516
2025/202617.041 455 1.664 3.317 926 3.192 2.686 1.600 581 596 1.424 385 215
Totale 32.220